Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 10/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211698 | 1.00 | MMP9 (0.43) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL14513402 | 0.87 | KMT2A (0.53) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL7207304 | 0.87 | KMT2A (0.53) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL7207300 | 0.87 | KMT2A (0.53) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL29706360 | 0.87 | KMT2A (0.53) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL7204427 | 0.87 | MMP9 (0.47) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL7204419 | 0.87 | MMP9 (0.47) | MMP9MMP8MMP14KMT2APYGL | |
| SCHEMBL7207452 | 0.87 | MMP9 (0.42) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7207456 | 0.87 | MMP9 (0.42) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL8205498 | 0.85 | MMP9 (0.43) | MMP9MMP8MMP14KMT2APYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |